Magunguna na tsawon lokaci don cutar ta Parkinson
Gudanar da cutar Parkinson ba tare da matsala ba. Ana amfani da maganin levodopa / carbidopa (wanda aka fi sani da Sinemet) a matsayin magani na zinari na magungunan motar cutar wannan cuta. Amma saboda gaskiyar cewa Sinemet yana aiki ne da gajeren lokaci, akwai lokutan tsakanin kwayoyin da wuraren bayyanar cututtuka sun sake komawa yayin da matakan miyagun ƙwayoyi suka sauke. Kuma yayin da cutar ta ci gaba, wannan magani ya zama ƙasa mai tasiri a sarrafa ikon inganta bayyanar cututtuka.
Magunguna suna buƙatar daukar ƙwayoyi masu yawa a cikin ƙoƙari don kauce wa "lokacin da aka yanke" inda aka yi amfani da maganin miyagun ƙwayoyi.
Wata hanyar da za ta fi amfani da ita zai zama wata hanyar da za ta sake levodopa / carbidopa da sannu a hankali, ta ba da matakan maganin maganin da ya rage kuma rage karuwar bayyanar cututtuka. Wannan yana nufin mahimmancin "lokaci mai tsawo" ga marasa lafiya na Parkinson.
Yadda Yake aiki
An yarda da Rytary a maganin cutar ta Parkinson. Yana da cikakkiyar suturar murya na carbidopa / levodopa, wanda aka yi amfani dashi a shekarun da suka gabata a cikin sakin da aka ba shi (wanda aka sani da sunan mai suna Sinemet). Ba kamar wanda ya riga ya kasance ba, tare da Rytary, duk da haka kuma matakan da ke dauke da carbidopa / levodopa suna samuwa a cikin jinin bayan an samu kashi daya.
Tabbatar da wannan miyagun ƙwayoyi ya zo bayan sakamakon babban babban gwaji na asibiti. Na farko, APEX-PD wani bincike ne da aka tsara (wanda aka bazu, wanda aka makantar da shi, mai sarrafa kansa) inda 381 marasa lafiya da cutar ta kwayar cutar ta samu ko ɗaya daga cikin maganin miyagun kwayoyi ko wuribo na tsawon makonni 30.
Sakamakon ya nuna haɓakawa a duk halayen motar, aiki na rayuwar yau da kullum da kuma kyakkyawar yanayin rayuwa.
Dangane daga binciken farko, jarrabawar gwaji ta biyu, ADVANCE-PD sun hada da batutuwa masu fama da ciwon daji da suka kamu da hawan motsi ko "lokacin jinkirta". 393 marasa lafiya sun kasance bazuwar samun Rytary ko sake-saki carbidopa-levodopa, magani mafi girma.
Wadanda suka karbi sabon magani sun fi raguwa da "jinkirin lokaci," wanda ya haifar da ƙarin "a lokaci" ba tare da dyskinesias ba idan aka kwatanta da wadanda ke karɓar magani na yau da kullum.
Me Ya Sa Makirci Mafi Girma?
Rytary ba shine farkon mikaccen shiri ba. Stalevo (wanda ke ƙunshe da levodopa, carbidopa, da ciwon zuciya) ya kasance a kasuwar tun lokacin kuma yana da tasiri sosai ga marasa lafiya. Menene ya sa wannan sabon tsarin ya fi kyau?
"Shaidar FDA ta RYTARY (mai suna Rye-TAR-ee) wani muhimmin ci gaba ne don kula da cutar ta Parkinson kuma ya samar da samfurin motar carbidopa-levodopa mai tsagewa wadda ke magance cutar Parkinson," in ji Fred Wilkinson, shugaban kasa da shugabancin Impax. Laboratories. "An tsara RYTARY don magance ɗaya daga cikin bukatun marasa lafiya da suka fi muhimmanci ga marasa lafiya da ke zaune tare da cutar Parkinson, wanda shine don rage yawan lokaci a lokacin da aka nuna rashin lafiyarsu."
Kodayake ba maganin da muke jiran ba, Rytary yana samar da karin miyagun ƙwayoyi a cikin kayan aiki na asibiti. Likitanka zai iya ƙayyade ko ya dace ya yi amfani da shi a cikin gudanar da cutarka ko kuma wani magani zai bada sakamako mafi kyau.
Sources:
Beck, James, MD. "Bidiyo: FDA ta amince da RYTARY &." Fidio: FDA ta amince da RYTARY & . Parkinson's Disease Foundation, 08 Jan. 2015. Yanar gizo.
"Impax Pharmaceuticals ta sanar da FDA amincewa da RYTARY ™ (Carbidopa da Levodopa) Sassauran 'Yan Sanda don Sake Kula da Cututtuka na Parkinson." Impax Pharmaceuticals sanar da FDA amince da RYTARY ™ (Carbidopa da Levodopa) Capsules Extended-Release ... Impax Laboratories Inc., 08 Jan. 2015. Yanar gizo.